Parkinson's DiseasePhase 2NCT01634243
A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
A Phase 2 study testing SPM 962 in people with Parkinson's Disease, run by Otsuka Pharmaceutical Co., Ltd. at 5 sites in Japan.
Trial summary
The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient following once-daily transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg. Read more about this study
- Who is it for?
- Ages 30 to 79 years
- Conditions the study is for
- Parkinson's Disease
- What is being tested?
- SPM 962
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 64 participants
- Where
- 5 sitesJapan
- Study dates
- Jan 2005to May 2006
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 79 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- For subject with early and advanced Parkinson's disease
- Subject diagnosed as having Parkinson's disease in accordance with "Diagnostic Criteria established by the Research Committee of MHLW-specified Intractable Neurodegenerative Diseases (1995)".
- Subject is 30 and more and less than 80 years of age at the time of informed consent.
- Gender and inpatient-outpatient status are not specified.
- For subject with early Parkinson's disease
- Hoehn \& Yahr stage 3 or less.
Show all 11Show fewer
- Subject who has not taken L-dopa within 28 days prior to initial administration of SPM 962.
- For subject with dvanced Parkinson's disease
- Hoehn \& Yahr stage 2-4.
- Subject is on a stable dose of L-dopa with no change in daily dose or dosing regimen for at least 7 days prior to the initial treatment of SPM 962.
- Subject has any of the following problematic symptoms; 1) Wearing off phenomenon 2) On and off phenomenon 3) Not well controlled with L-dopa due to adverse effect 4) Weakening of L-dopa efficacy.
Who cannot join
- Subject is on other dopamine agonist treatment within 7 days prior to the initial treatment. Subject is on cabergoline treatment within 14 days prior to the initial treatment.
- Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior.
- Subject has orthostatic hypotension.
- Subject has a history of epilepsy, convulsion and other.
- Subject has a complication of serious cardiac disorder or has the history.
- Subject has arrhythmia and treated with class 1a antiarrhythmic drugs (e.g. quinidine, procainamide etc.) or class 3 antiarrhythmic drugs (e.g. amiodarone, sotalol etc.).
Show all 19Show fewer
- At screening and baseline, subject develops serious ECG abnormality. Subjects has QTc-interval >450 msec at screening. Subject has QTc-interval >450 msec in males and >470 msec in females at baseline.
- Subject has congenital long QT syndrome.
- Subject has hypokalaemia.
- Subject has a total bilirubin >= 3.0 mg/dL or AST(GOT) or ALT(GPT) greater than 2.5 times of the upper limit of the reference range (or >= 100 IU/L).
- Subject has BUN >= 25 mg/dL or serum creatinine >= 2.0 mg/dl.
- Subject has a history of allergic reaction to topical agents such as transdermal patch.
- Subject is pregnant or nursing or woman who plans pregnancy during the trial.
- Subject is receiving therapy with prohibited drug specified in the study protocol.
- Subject has a history of pallidotomy, thalamotomy, deep brain stimulation or fetal tissue transplant.
- Subject has dementia.
- Subject is unable to give consent.
- Subject is participating in another trial of an investigational drug or done so within 6 months prior to the initial treatment.
- Investigator judges that subject is inappropriate as a study subject with other reasons.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Japan5 sites
Study site
Kanto Region
Study site
Kinki Region
Study site
Kyushu Region
Study site
Shikoku Region
Study site
Tohoku Region
About this study
Official title: A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient following once-daily transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg. (The administration period will consist of a standard 8-week dose-titration period, 4-week dose-maintenance period, and a dose de-escalation period) Exploratory evaluation of each patient's maintenance dose will also be conducted with attention to patient safety. The relationship of pharmacokinetics, safety, and efficacy will also be examined.
- Conditions
- Parkinson's Disease
- Being tested
- SPM 962
- Keywords
- SPM 962, rotigotine, Parkinson's disease
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SPM 962Drug
Also called rotigotine
SPM 962 transdermal patch once a daily up to 36.0 mg/day
| Study group | Role | What they receive |
|---|---|---|
| SPM 962 | Experimental | SPM 962 transdermal patch Receives: Drug: SPM 962 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maintenance Dose of the SPM962
The maintenance dose of the SPM 962 was examined based on the safety and efficacy.
Measured: Up to 12 weeks after dosing
Secondary outcomes (10)
Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters
Incidence and severity of adverse events, vital signs, and laboratory parameters following the initiation of study treatment.
Measured: Up to 12 weeks after dosing
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score and Part 3 sum at 12 weeks after dosing.
UPDRS is a scale for monitoring Parkinson's Disease-related disability and impairment. The UPDRS consists of the following four sub-scales. Part 1: Mentation, Part 2: Activities of Daily Living, Part 3: Motor, Part 4: Complications. Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: baseline, 12 weeks after dosing
UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in UPDRS Part 2 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: Baseline, 12 weeks after dosing
UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in UPDRS Part 3 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: Baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (on state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: Baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: Baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in UPDRS Part 2 sum score (average score of on state and off state) at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: Baseline, 12 weeks after dosing
Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in Total of UPDRS Part 2 sum score (average score of on state and off state) and Part 3 sum score at 12 weeks after dosing.
UPDRS sub-scale Part 2 assesses 13 items and Part 3 assesses 14 items. Each item is scored from 0 (normal) to 4 (severe). The sum score serves as the sub-scale score. A higher score indicates a greater severity of symptoms. Thus a decrease in the scores means improvement.
Measured: Baseline, 12 weeks after dosing
Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Mean change (LOCF) from baseline in off time at 12 weeks after dosing.
Measured: Baseline, 12 weeks after dosing
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jul 2012 (estimated)
- Study startJan 2005
- Primary completionMay 2006
- Study completionMay 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Kyoji Imaoka, Mr, Study director, Otsuka Pharmaceutical Co., Ltd.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01634243
- Sponsor's protocol ID
- 243-03-001
- Status last verified
- Feb 2014
- First submitted
- 27 Jun 2012
- Last updated
- 19 Mar 2014
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 19 Mar 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients
- ClinicalTrials.gov ID
- NCT01634243
- Acronym / sponsor ID
- 243-03-001
- Conditions
- Parkinson's Disease
- Keywords
- SPM 962, rotigotine, Parkinson's disease
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Jan 2005
- Primary completion
- May 2006 (actual)
- Study completion
- May 2006 (actual)
- First posted
- 6 Jul 2012 (estimated)
- Results
- Posted 19 Mar 2014
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this trial is to establish the maximum maintenance dose of SPM 962 in patients with Parkinson's disease in a multi-center, uncontrolled, open-label study by conducting safety evaluation of each patient following once-daily transdermal doses of SPM 962 within a range of 4.5 to 36.0 mg. (The administration period will consist of a standard 8-week dose-titration period, 4-week dose-maintenance period, and a dose de-escalation period) Exploratory evaluation of each patient's maintenance dose will also be conducted with attention to patient safety. The relationship of pharmacokinetics, safety, and efficacy will also be examined.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SPM 962 | Experimental | Drug: SPM 962SPM 962 transdermal patch |
Who may qualify
- Ages
- 30 to 79 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- For subject with early and advanced Parkinson's disease
- For subject with early Parkinson's disease
- For subject with dvanced Parkinson's disease
Key exclusion criteria (19 listed)
- Subject is on other dopamine agonist treatment within 7 days prior to the initial treatment. Subject is on cabergoline treatment within 14 days prior to the initial treatment.
- Subject has psychiatric symptoms, e.g. confusion, hallucination, delusion, excitation, delirium, abnormal behavior.
- Subject has orthostatic hypotension.
- Subject has a history of epilepsy, convulsion and other.
- Subject has a complication of serious cardiac disorder or has the history.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SPM 962Also: rotigotineSPM 962 transdermal patch once a daily up to 36.0 mg/day | Drug | SPM 962 |
Primary outcome
Maintenance Dose of the SPM962
Time frame: Up to 12 weeks after dosing
The maintenance dose of the SPM 962 was examined based on the safety and efficacy.
10 secondary outcomes
Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters
Time frame: Up to 12 weeks after dosing
Total of Unified Parkinson's Disease Rating Scale (UPDRS) Part 2 Sum Score and Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Time frame: baseline, 12 weeks after dosing
UPDRS Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Time frame: baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Time frame: Baseline, 12 weeks after dosing
UPDRS Part 3 Sum Score for Early Parkinson's Disease Without Concomitant L-dopa Therapy
Time frame: Baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score (on State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.
Time frame: Baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score (Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy.
Time frame: Baseline, 12 weeks after dosing
UPDRS Part 2 Sum Score (Average Score of on State and Off State) for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Time frame: Baseline, 12 weeks after dosing
Total of UPDRS Part 2 Sum Score (Average Score of on State and Off State) and Part 3 Sum Score for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Time frame: Baseline, 12 weeks after dosing
Off Time for Advanced Parkinson's Disease With Concomitant L-dopa Therapy
Time frame: Baseline, 12 weeks after dosing
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 Mar 2014.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Parkinson's Disease
Not yet recruitingObservational study
Perception of Action Opportunities for Obstacle Crossing in Parkinson's Disease
PARKINSON DISEASE (Disorder), Older Adults (65-85 Years)
Enrolling by invitationObservational study
Genetic Studies of Lysosomal Storage Disorders
Lysosomal Storage Disorders, Gaucher Disease
RecruitingObservational study
Evaluation and Treatment of Neurosurgical Disorders
Neurologic Disorders
Active, not recruitingPhase 2
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Thymoma, Thymic Carcinoma
RecruitingPhase 1/2
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Carcinoma, Non-Small-Cell Lung
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kyoji Imaoka, Mr study director
Otsuka Pharmaceutical Co., Ltd.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SPM 962 in people with Parkinson's Disease, run by Otsuka Pharmaceutical Co., Ltd. at 5 sites in Japan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 Mar 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Japan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 19 Mar 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maintenance Dose of the SPM962 (time frame: Up to 12 weeks after dosing). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2014; AzTrials last refreshed its copy on 30 Oct 2026.